Crescent Biopharma (CBIO)
Develops antibody medicines for solid tumors through bispecific and ADC programs.
Something off on this page? Send us feedback.
Develops investigational antibody therapies for solid tumors, centered on CR-001, a PD-1 × VEGF bispecific, and an antibody-drug conjugate portfolio. Its public listing followed a reverse recapitalization with GlycoMimetics, while progress depends on clinical execution and a China program with Kelun-Biotech.
Advances CR-001, an investigational tetravalent PD-1 × VEGF bispecific antibody, alongside antibody-drug conjugate programs for solid tumors. The portfolio draws on candidates licensed from Paragon Therapeutics for treating solid tumors and uses multiple modalities and established targets.
Clinical development includes the global Phase 1/2 ASCEND trial of CR-001 across multiple solid-tumor types and a Phase 1/2 CR-003 trial in China. The company expects CR-002 to enter the clinic.
Nasdaq trading began after a reverse recapitalization with GlycoMimetics. Program progress is tied to clinical execution and the China trial involving Kelun-Biotech.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 1, 2026 | HC Wainwright & Co. | Downgrade | ||
| Feb 26, 2026 | Stifel Nicolaus | Target | Target: $32 | Target: $29 |
| Jan 28, 2026 | Piper Sandler | Target | Target: — | Target: $35 |
| Jan 21, 2026 | Guggenheim | Target | Target: — | Target: $35 |
| Dec 4, 2025 | Stifel Nicolaus | Target | Target: — | Target: $32 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $171.6M · Total debt $1.4M · Total assets $182.8M · Shareholders' equity $163.3M
- Revenue
- $0
- Operating income
- −$26.4M
- Net income
- −$22.7M
No dividends on record.
| Institutions | 78.52% | 29.16M shares | |
|---|---|---|---|
| 82 holders · as of Jun 30, 2026 | |||
| Insiders | 1.52% | 563.6K shares | |
| 8 holders · as of Sep 18, 2026 | |||
| Other | 19.96% | 7.42M shares | |
| remainder | |||
37.14M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 11.13% | 4.13M | as of Jun 30, 2026 |
BVF Inc/ILInstitution | 7.40% | 2.75M | as of Jun 30, 2026 |
Fairmount Funds Management LLCInstitution | 7.40% | 2.75M | as of Jun 30, 2026 |
VR Adviser, LLCInstitution | 5.74% | 2.13M | as of Jun 30, 2026 |
Logos Global Management LPInstitution | 5.12% | 1.90M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 18, 2026 | Jonathan McNeill | officer: President and COO | −3,839 | $16.71 |
| Sep 16, 2026 | Jonathan McNeill | officer: President and COO | −731 | $17.90 |
| Sep 18, 2026 | Joshua T. Brumm | director, officer: Chief Executive Officer | −7,837 | $16.71 |
| Sep 16, 2026 | Joshua T. Brumm | director, officer: Chief Executive Officer | −1,610 | $17.90 |
| Sep 16, 2026 | Barbara Harlin Bispham | officer: See Remarks | −620 | $17.90 |
- Summit Therapeutics
Licensed PD-1 × VEGF bispecific for global NSCLC development
- BioNTech (ADR)
PD-L1 × VEGF bispecific in global NSCLC and solid-tumor trials
- Merck
PD-1 × VEGF bispecific and marketed PD-1 oncology backbone
- Pfizer
PD-1 × VEGF bispecific and integrin β6 ADC programs in solid tumors
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Crescent Biopharma | $15.73 | −4.29% | $610.6M | — | — | 51.4 | — |
| Summit Therapeutics | $16.95 | −0.98% | $13.66B | — | — | — | — |
| BioNTech (ADR) | $100.74 | −0.13% | $25.34B | — | — | 8.4 | −60.7% |
| Merck | $149.73 | −0.79% | $372.73B | 120.7 | 17.3 | 5.6 | +5.1% |
| Pfizer | $28.05 | +0.41% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Median | 78.8 | 13.7 | 5.6 | +2.6% |